½ÃÀ庸°í¼­
»óǰÄÚµå
1775545

µðÁöÅÐ º´¸®ÇÐ ½ÃÀå : ¿¹Ãø(2025-2030³â)

Digital Pathology Market - Forecasts from 2025 to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Knowledge Sourcing Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® 150 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ µðÁöÅÐ º´¸®ÇÐ ½ÃÀå ±Ô¸ð´Â 2025³â 10¾ï 7,825¸¸ 5,000´Þ·¯¿¡¼­ 2030³â¿¡´Â 23¾ï 501¸¸ 1,000´Þ·¯·Î, CAGR 16.41%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ º¸°í¼­´Â ¼¼°è µðÁöÅÐ º´¸®ÇÐ(Digital Pathology) ½ÃÀåÀ» Á¾ÇÕÀûÀ¸·Î ºÐ¼®ÇÏ¿© ÀÌ Çõ½ÅÀûÀÎ ÇコÄÉ¾î ºÐ¾ß¸¦ Çü¼ºÇÏ´Â ½ÃÀå µ¿Çâ, ±â¼ú ¹ßÀü, °æÀï Àü·«¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ ¾÷°è Àü¹®°¡µé¿¡°Ô Á¦°øÇÕ´Ï´Ù. Á¦Ç° À¯Çü, ÃÖÁ¾»ç¿ëÀÚ, ¿ëµµ, Áö¿ªº°·Î ¼¼ºÐÈ­ÇÏ¿© ½ÃÀå ÃËÁø¿äÀÎ, ½ÃÀå ¾ïÁ¦¿äÀÎ, ±âȸ µî ÁÖ¿ä ½ÃÀå ¿ªÇÐÀ» ޱ¸ÇÕ´Ï´Ù. µðÁöÅÐ º´¸®ÇÐ ½ÃÀå Á¶»ç´Â Àü·«Àû ÀÇ»ç°áÁ¤À» Áö¿øÇϵµ·Ï ¼³°èµÇ¾úÀ¸¸ç, ÀÌÇØ°ü°èÀÚµéÀÌ µðÁöÅÐ º´¸®ÇÐ ¼Ö·ç¼ÇÀÇ ÁøÈ­Çϴ ȯ°æ¿¡¼­ »ì¾Æ³²À» ¼ö ÀÖµµ·Ï µ¥ÀÌÅÍ¿¡ ±â¹ÝÇÑ ¿¹Ãø, ±ÔÁ¦ °í·Á»çÇ×, °æÀï Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

Á¶»ç °³¿ä

ÀÌ º¸°í¼­´Â µðÁöÅÐ º´¸®ÇÐ ¼¼°è ½ÃÀåÀ» Á¦Ç° À¯Çü(½ºÄ³³Ê, ¼ÒÇÁÆ®¿þ¾î, Á¤º¸ °ü¸® ½Ã½ºÅÛ, ½ºÆ®·¹Ä¡ Ŭ¶ó¿ìµå ¼Ö·ç¼Ç, Åë½Å ³×Æ®¿öÅ© ½Ã½ºÅÛ), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø, Áø´Ü ½ÇÇè½Ç, Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷, Çмú ¹× ¿¬±¸±â°ü, À§Å¹ ¿¬±¸±â°ü), ¿ëµµ(½Å¾à °³¹ß, Áúº´ Áø´Ü, Çмú ¿¬±¸, ÅÚ·¹ÆÄ½Ã, ±³À°), Áö¿ª(ºÏ¹Ì, ³²¹Ì, À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«, ¾Æ½Ã¾ÆÅÂÆò¾ç)À¸·Î ºÐ·ùÇÏ¿© Á¶»çÇϰí ÀÖ½À´Ï´Ù. Porter's Five Forces ºÐ¼®, »ê¾÷ ¹ë·ùüÀÎ ºÐ¼®, ½ÃÀå Á¡À¯À² Æò°¡ µî źźÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚµéÀÌ ¼ºÀå ±âȸ¸¦ Ȱ¿ëÇÒ ¼ö ÀÖ´Â Àü·«Àû Á¦¾È°ú ±ÔÁ¦¿¡ ´ëÇÑ ÀλçÀÌÆ®µµ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. º´¸®ÇÐ ºÐ¾ß¿¡¼­ÀÇ AI µµÀÔ°ú ¿ø°Ý Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä µî ÁÖ¿ä ÃËÁø¿äÀΰú ³ôÀº µµÀÔ ºñ¿ë ¹× ±ÔÁ¦ º¹À⼺ µîÀÇ °úÁ¦¸¦ °­Á¶Çϰí ÀÖ½À´Ï´Ù.

°æÀï ȯ°æ ¹× ºÐ¼®

µðÁöÅÐ º´¸®ÇÐ ½ÃÀå Á¶»çÀÇ °æÀï Á¤º¸ ¼½¼Ç¿¡¼­´Â ÁÖ¿ä ±â¾÷µéÀÌ ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­Çϱâ À§ÇÑ Àü·«Àû ³ë·ÂÀ» ´Ù·ç°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Leica Biosystems Nussloch GmbH(Danaher)´Â 2024³â Aperio GT 450 DX ½ºÄ³³ÊÀÇ ¾÷±×·¹ÀÌµå ¹öÀüÀ» Ãâ½ÃÇÏ¿© ¹Ì±¹ Àü¿ªÀÇ Áø´Ü ½ÇÇè½Ç¿¡¼­ º¸´Ù ½Å¼ÓÇÑ Áúº´ Áø´ÜÀ» À§ÇØ AI ±â¹Ý À̹ÌÁö ºÐ¼®À» °­È­Çß½À´Ï´Ù. À̹ø °³¹ß·Î ¶óÀÌÄ« ¹ÙÀÌ¿À½Ã½ºÅÛÁî´Â ÇÏÀÌ ½½·çDz ½ºÄ³´× ¼Ö·ç¼ÇÀÇ ¸®´õ½±À» °­È­ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¸¶Âù°¡Áö·Î, Koninklijke Philips N.V.´Â À¯·´ ÁÖ¿ä º´¿ø ³×Æ®¿öÅ©¿ÍÀÇ 2025³â Àü·«Àû Á¦ÈÞ¸¦ ÅëÇØ µðÁöÅÐ º´¸®ÇÐ Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇÏ°í µ¶Àϰú ÇÁ¶û½º¿¡¼­ ¿ø°Ý º´¸®ÇÐ ¼­ºñ½º¸¦ °­È­Çϱâ À§ÇØ IntelliSite Ç÷§ÆûÀ» Ŭ¶ó¿ìµå ±â¹Ý ½ºÆ®·¹½º ¼Ö·ç¼Ç°ú ÅëÇÕÇß½À´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý ½ºÆ®·¹½º ¼Ö·ç¼Ç°ú ÅëÇÕÇÏ¿´½À´Ï´Ù. ÀÌ Á¶»ç¿¡´Â ½ÃÀå Á¡À¯À² ºÐ¼®, ÇÕº´, Àμö, ÀμöÇÕº´, °æÀï »óȲÀ» ÇÑ´«¿¡ º¼ ¼ö ÀÖ´Â °æÀï ´ë½Ãº¸µåµµ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

°á·Ð

ÀÌ º¸°í¼­´Â µðÁöÅÐ º´¸®ÇÐ ½ÃÀåÀÇ º¹À⼺À» ÀÌÇØÇϰíÀÚ ÇÏ´Â ¾÷°è Àü¹®°¡¿¡°Ô ÇʼöÀûÀÎ ÀÚ·áÀÔ´Ï´Ù. »ó¼¼ÇÑ ¼¼ºÐÈ­, ±â¼ú Àü¸Á, °æÀï Á¤º¸¸¦ Á¦°øÇÔÀ¸·Î½á ÀÌ Á¶»ç´Â ±âȸ¸¦ ½Äº°Çϰí È¿°úÀûÀÎ Àü·«À» ¼ö¸³ÇÒ ¼ö ÀÖ´Â °ß°íÇÑ ÇÁ·¹ÀÓ¿öÅ©¸¦ Á¦°øÇÕ´Ï´Ù. Leica Biosystems Nussloch GmbH, Koninklijke Philips N.V. µî ÁÖ¿ä ±â¾÷µéÀÌ AI ±â¹Ý ½ºÄ³´× ¹× Ŭ¶ó¿ìµå ÅëÇÕ ÅÚ·¹ÆÄ¼Ö·ÎÁö ¼Ö·ç¼ÇÀÇ Çõ½ÅÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, µðÁöÅÐ º´¸®ÇÐ ½ÃÀå °æÀïÀº ÀÌ ¿ªµ¿ÀûÀÌ°í ±Þ¼ºÀåÇϰí ÀÖ´Â ±Þ¼ºÀåÇÏ´Â ¾÷°è¿¡¼­ ÀÌÇØ°ü°èÀÚµéÀÌ °æÀï·ÂÀ» À¯ÁöÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇϰí ÀÖ½À´Ï´Ù.

º» º¸°í¼­ÀÇ ÁÖ¿ä ÀåÁ¡

  • ÅëÂû·Â ÀÖ´Â ºÐ¼® : ÁÖ¿ä Áö¿ª ¹× ½ÅÈï Áö¿ª, °í°´ ºÎ¹®, Á¤ºÎ Á¤Ã¥ ¹× »çȸ°æÁ¦Àû ¿äÀÎ, ¼ÒºñÀÚ ¼±È£µµ, »ê¾÷, ±âŸ ÇÏÀ§ ºÎ¹®¿¡ ÃÊÁ¡À» ¸ÂÃá ½ÉÃþÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.
  • °æÀï »óȲ : ¼¼°è ÁÖ¿ä ±â¾÷µéÀÌ Ã¤ÅÃÇϰí ÀÖ´Â Àü·«Àû ¿òÁ÷ÀÓÀ» ÀÌÇØÇϰí, ÀûÀýÇÑ Àü·«À» ÅëÇÑ ½ÃÀå ħÅõ °¡´É¼ºÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • ½ÃÀå µ¿Çâ°ú ÃËÁø¿äÀÎ : ¿ªµ¿ÀûÀÎ ¿äÀΰú ¸Å¿ì Áß¿äÇÑ ½ÃÀå µ¿Çâ, ±×¸®°í À̵éÀÌ ÇâÈÄ ½ÃÀå ¹ßÀüÀ» ¾î¶»°Ô Çü¼ºÇÒ °ÍÀÎÁö¿¡ ´ëÇØ ¾Ë¾Æº¾´Ï´Ù.
  • ½ÇÇà °¡´ÉÇÑ Á¦¾È : ¿ªµ¿ÀûÀΠȯ°æ ¼Ó¿¡¼­ »õ·Î¿î ºñÁî´Ï½º ½ºÆ®¸²°ú ¼öÀÍÀ» ¹ß±¼Çϱâ À§ÇÑ Àü·«Àû ÀÇ»ç°áÁ¤¿¡ ÀλçÀÌÆ®¸¦ Ȱ¿ëÇÕ´Ï´Ù.
  • ±¤¹üÀ§ÇÑ »ç¿ëÀÚ Áö¿ø : ½ºÅ¸Æ®¾÷, ¿¬±¸±â°ü, ÄÁ¼³ÅÏÆ®, Áß¼Ò±â¾÷, ´ë±â¾÷¿¡ À¯ÀÍÇÏ°í ºñ¿ë È¿À²ÀûÀÔ´Ï´Ù.

º¸°í¼­ÀÇ ÁÖ¿ä Ȱ¿ë ¹æ¹ý

»ê¾÷ ¹× ½ÃÀå ÀλçÀÌÆ®, »ç¾÷ ±âȸ Æò°¡, Á¦Ç° ¼ö¿ä ¿¹Ãø, ½ÃÀå ÁøÀÔ Àü·«, Áö¸®Àû È®Àå, ¼³ºñ ÅõÀÚ °áÁ¤, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ© ¹× ¿µÇâ, ½ÅÁ¦Ç° °³¹ß, °æÀïÀÇ ¿µÇâ

Á¶»ç ¹üÀ§

  • 2022-2024³â ½ÇÀû µ¥ÀÌÅÍ¿Í 2025-2030³â ¿¹Ãø µ¥ÀÌÅÍ
  • ¼ºÀå ±âȸ, µµÀü°úÁ¦, °ø±Þ¸Á Àü¸Á, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, µ¿Ç⠺м®
  • °æÀï»ç Æ÷Áö¼Å´×, Àü·« ¹× ½ÃÀå Á¡À¯À² ºÐ¼®
  • ºÎ¹® ¹× ±¹°¡¸¦ Æ÷ÇÔÇÑ Áö¿ªº° ¸ÅÃâ ¼ºÀå ¹× ¿¹Ãø ºÐ¼®
  • ±â¾÷ °³¿ä(ÁÖ·Î Àü·«, Á¦Ç°, À繫 Á¤º¸, ÁÖ¿ä ¹ßÀü µî)

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå ÇöȲ

  • ½ÃÀå °³¿ä
  • ½ÃÀå Á¤ÀÇ
  • Á¶»ç ¹üÀ§
  • ½ÃÀå ¼¼ºÐÈ­

Á¦3Àå ºñÁî´Ï½º »óȲ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • Porter's Five Forces ºÐ¼®
  • ¾÷°è ¹ë·ùüÀÎ ºÐ¼®
  • Á¤Ã¥°ú ±ÔÁ¦
  • Àü·«Àû Á¦¾È

Á¦4Àå ±â¼ú Àü¸Á

Á¦5Àå µðÁöÅÐ º´¸®ÇÐ ½ÃÀå : Á¦Ç° À¯Çüº°

  • ¼Ò°³
  • ½ºÄ³³Ê
  • ¼ÒÇÁÆ®¿þ¾î
  • Á¤º¸ °ü¸® ½Ã½ºÅÛ
  • ½ºÅ丮Áö¡¤Å¬¶ó¿ìµå ¼Ö·ç¼Ç
  • Åë½Å¡¤³×Æ®¿öÅ© ½Ã½ºÅÛ

Á¦6Àå µðÁöÅÐ º´¸®ÇÐ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¼Ò°³
  • º´¿ø
  • Áø´Ü °Ë»ç½Ç
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • Çмú¡¤¿¬±¸±â°ü
  • ¼öŹ¿¬±¸±â°ü(CRO)

Á¦7Àå µðÁöÅÐ º´¸®ÇÐ ½ÃÀå : ¿ëµµº°

  • ¼Ò°³
  • Drug Discovery & Development
  • Áúº´ Áø´Ü
  • Çмú ¿¬±¸
  • ¿ø°Ýº´¸®Áø´Ü
  • Æ®·¹À̴ס¤±³À°

Á¦8Àå µðÁöÅÐ º´¸®ÇÐ ½ÃÀå : Áö¿ªº°

  • ¼Ò°³
  • ºÏ¹Ì
    • Á¦Ç° À¯Çüº°
    • ÃÖÁ¾»ç¿ëÀÚº°
    • ¿ëµµº°
    • ±¹°¡º°
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
  • ³²¹Ì
    • Á¦Ç° À¯Çüº°
    • ÃÖÁ¾»ç¿ëÀÚº°
    • ¿ëµµº°
    • ±¹°¡º°
      • ºê¶óÁú
      • ¾Æ¸£ÇîÆ¼³ª
      • ±âŸ
  • À¯·´
    • Á¦Ç° À¯Çüº°
    • ÃÖÁ¾»ç¿ëÀÚº°
    • ¿ëµµº°
    • ±¹°¡º°
      • ¿µ±¹
      • µ¶ÀÏ
      • ÇÁ¶û½º
      • ½ºÆäÀÎ
      • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Á¦Ç° À¯Çüº°
    • ÃÖÁ¾»ç¿ëÀÚº°
    • ¿ëµµº°
    • ±¹°¡º°
      • »ç¿ìµð¾Æ¶óºñ¾Æ
      • ¾Æ¶ø¿¡¹Ì¸®Æ®
      • ±âŸ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Á¦Ç° À¯Çüº°
    • ÃÖÁ¾»ç¿ëÀÚº°
    • ¿ëµµº°
    • ±¹°¡º°
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • Çѱ¹
      • ´ë¸¸
      • ±âŸ

Á¦9Àå °æÀï ȯ°æ°ú ºÐ¼®

  • ÁÖ¿ä ±â¾÷°ú Àü·« ºÐ¼®
  • ½ÃÀå Á¡À¯À² ºÐ¼®
  • ÇÕº´¡¤Àμö¡¤ÇùÁ¤¡¤Çù¾÷
  • °æÀï ´ë½Ãº¸µå

Á¦10Àå ±â¾÷ °³¿ä

  • Leica Biosystems Nussloch GmbH(Danaher)
  • Hamamatsu Photonics, Inc.
  • Koninklijke Philips N.V.
  • Olympus Corporation
  • F. Hoffmann-La Roche Ltd.
  • Mikroscan Technologies, Inc.
  • Epredia(3DHISTECH Ltd.)
  • Visiopharm A/S
  • Huron Technologies International Inc.
  • ContextVision AB

Á¦11Àå ºÎ·Ï

  • ÅëÈ­
  • °¡Á¤
  • ±âÁØ ¿¬µµ¿Í ¿¹Ãø ¿¬µµ ŸÀÓ¶óÀÎ
  • ÀÌÇØ°ü°èÀÚ¿¡ ´ëÇÑ ÁÖ¿ä ÀÌÁ¡
  • Á¶»ç ¹æ¹ý
  • ¾à¾î
ksm

The Digital Pathology Market is expected to grow from USD 1,078.255 million in 2025 to USD 2,305.011 million in 2030, at a CAGR of 16.41%.

The Digital Pathology Market Study delivers a comprehensive analysis of the global digital pathology market, providing industry experts with critical insights into market trends, technological advancements, and competitive strategies shaping this transformative healthcare sector. This study explores key market dynamics, including drivers, restraints, and opportunities, with detailed segmentation by product type, end-user, application, and geography. Designed to support strategic decision-making, the Digital Pathology Market Study equips stakeholders with data-driven forecasts, regulatory insights, and competitive intelligence to navigate the evolving landscape of digital pathology solutions.

Study Overview

The Digital Pathology Market Study examines the global digital pathology market, segmented by product type (Scanners, Software, Information Management Systems, Storage & Cloud Solutions, Communication & Networking Systems), end-user (Hospitals, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations), application (Drug Discovery and Development, Disease Diagnosis, Academic Research, Telepathology, Training & Education), and geography (North America, South America, Europe, Middle East and Africa, Asia Pacific). It includes robust analyses such as Porter's Five Forces Analysis, Industry Value Chain Analysis, and market share evaluations, alongside strategic recommendations and regulatory insights to help stakeholders capitalize on growth opportunities. The study highlights key driving factors, such as the adoption of AI in pathology and demand for remote diagnostics, and challenges, including high implementation costs and regulatory complexities.

Competitive Environment and Analysis

In the competitive intelligence section of the Digital Pathology Market Study, key players are highlighted for their strategic initiatives to strengthen market presence. For instance, Leica Biosystems Nussloch GmbH (Danaher) launched an upgraded version of its Aperio GT 450 DX scanner in 2024, featuring enhanced AI-driven image analysis for faster disease diagnosis in diagnostic laboratories across the United States. This development reinforces Leica Biosystems' leadership in high-throughput scanning solutions. Similarly, Koninklijke Philips N.V. expanded its digital pathology portfolio through a 2025 strategic collaboration with a leading European hospital network, integrating its IntelliSite platform with cloud-based storage solutions to enhance telepathology services in Germany and France. The study also includes market share analysis, mergers, acquisitions, and a competitive dashboard to provide a holistic view of the competitive landscape.

Conclusion

The Digital Pathology Market Study is an essential resource for industry experts seeking to understand the complexities of the digital pathology market. By offering detailed segmentation, technological outlooks, and competitive intelligence, this study provides a robust framework for identifying opportunities and formulating effective strategies. With leading players like Leica Biosystems Nussloch GmbH and Koninklijke Philips N.V. driving innovation in AI-enhanced scanning and cloud-integrated telepathology solutions, the Digital Pathology Market Study empowers stakeholders to stay competitive in this dynamic and rapidly growing industry.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Different segments covered under the digital pathology market report are as below:

By Product Type

  • Scanners
  • Software
  • Information Management Systems
  • Storage & Cloud Solutions
  • Communication & Networking Systems

By End-User

  • Hospitals
  • Diagnostic Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Contract Research Organizations (CROs)

By Application

  • Drug Discovery and Development
  • Disease Diagnosis
  • Academic Research
  • Telepathology
  • Training & Education

By Geography

  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. DIGITAL PATHOLOGY MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Scanners
  • 5.3. Software
  • 5.4. Information Management Systems
  • 5.5. Storage & Cloud Solutions
  • 5.6. Communication & Networking Systems

6. DIGITAL PATHOLOGY MARKET BY END-USER

  • 6.1. Introduction
  • 6.2. Hospitals
  • 6.3. Diagnostic Laboratories
  • 6.4. Pharmaceutical & Biotechnology Companies
  • 6.5. Academic & Research Institutes
  • 6.6. Contract Research Organizations (CROs)

7. DIGITAL PATHOLOGY MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Drug Discovery and Development
  • 7.3. Disease Diagnosis
  • 7.4. Academic Research
  • 7.5. Telepathology
  • 7.6. Training & Education

8. DIGITAL PATHOLOGY MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Product Type
    • 8.2.2. By End-User
    • 8.2.3. By Application
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Product Type
    • 8.3.2. By End-User
    • 8.3.3. By Application
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Product Type
    • 8.4.2. By End-User
    • 8.4.3. By Application
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Product Type
    • 8.5.2. By End-User
    • 8.5.3. By Application
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Product Type
    • 8.6.2. By End-User
    • 8.6.3. By Application
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. India
      • 8.6.4.4. South Korea
      • 8.6.4.5. Taiwan
      • 8.6.4.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Leica Biosystems Nussloch GmbH (Danaher)
  • 10.2. Hamamatsu Photonics, Inc.
  • 10.3. Koninklijke Philips N.V.
  • 10.4. Olympus Corporation
  • 10.5. F. Hoffmann-La Roche Ltd.
  • 10.6. Mikroscan Technologies, Inc.
  • 10.7. Epredia (3DHISTECH Ltd.)
  • 10.8. Visiopharm A/S
  • 10.9. Huron Technologies International Inc.
  • 10.10. ContextVision AB

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key benefits for the stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦